Phosphodiesterase type 5 inhibitors as treatment for erectile dysfunction: a webinar-based poll unveiling perceptions of healthcare professionals

Author:

Moazin Maher S1,Baazeem Abdulaziz2,Al-Bakri Ayman3,Dayel Adel Al4,Amir Ashraf5,Sifri Saud Al6,Reda Mona7,Bashraheel Fahad8,Alfakhri Abdullah9,Hamdy Yousef10,Elshaer Fayez11

Affiliation:

1. Assistant Professor of Urology, King Saud University for Health Science, Riyadh, Saudi Arabia

2. Associate Professor of Urology, Umm Al-Qura University, Makkah, Saudi Arabia

3. Urology consultant, Male Reproductive Health specialist, Security Forces Hospital, Riyadh, Saudi Arabia

4. Consultant Urologist/Andrologist, Director of Men's Health Clinic, Dammam, Saudi Arabia

5. Consultant Family Medicine, International Medical Center, Jeddah, Saudi Arabia

6. Consultant Endocrinologist, Department of Endocrinology & Diabetes, Alhada Armed Forces Hospital, Taif, Saudi Arabia

7. Professor of Psychiatry, Ain Shams University, Cairo, Egypt

8. Urologist/Andrologist, Dr. Soliman Fakeeh Hospital, Jeddah, Saudi Arabia

9. Consultant Andrology/Male Infertility, King Fahad Medical City – Main Hospital, Riyadh, Saudi Arabia

10. Medical Advisor, Viatris, Riyadh, Saudi Arabia

11. Professor of Cardiology, King Fahad cardiac center, King Khaled university hospital, King Saud university, Riyadh, Saudi Arabia- National heart institute, Cairo, Egypt

Abstract

Aim: Erectile dysfunction (ED) is marked by a recurring incapacity to achieve or uphold a satisfactory erection during sexual activities. The study aims to increase awareness about male reproductive health, dispel misconceptions about ED and encourage physician-patient discussions. Materials & methods: A live online poll was conducted during a 3-day webinar titled “Turning the Tide of Men's Health” organized by Viatris™ in collaboration with the Saudi Society of Family and Community Medicine and attended by healthcare professionals (HCPs) from diverse specialties. The attendees voluntarily responded to nine poll questions on adherence to ED medication, use of phosphodiesterase type 5 inhibitors (PDE5is) as cure versus management of ED and patients' challenges. The responses to the poll questions were recorded and assessed to understand the perceptions of HCPs. Results: The poll garnered 10,423 responses from 5831 attendees on the second day of the webinar. The key findings included HCPs' perceptions that PDE5is contribute to ED management not complete cure. The respondents acknowledged that adherence to ED medications might decline on days without planned sexual activity, and long-term adherence on a daily PDE5i is exhibited by a relatively modest percentage of ED patients. The consensus among respondents was that PDE5is do not enhance or generate sexual desire, and the daily schedule of ED treatment may be burdensome for some patients. Conclusion: The findings from this poll offer insights into the perspectives of HCPs regarding the usage of PDE5is to treat ED. Responders of the poll generally agreed that PDE5is can help manage ED without affecting desire, though adherence may be lower on days without planned sexual activity. Furthermore, most respondents acknowledged that adhering to a daily pill regimen posed a greater burden than waiting for the medication to take effect.

Publisher

Becaris Publishing Limited

Reference28 articles.

1. Management of male erectile dysfunction: from the past to the future;Wang CM;Front. Endocrinol. (Lausanne).,2023

2. Pharmacology and perspectives in erectile dysfunction in man;Mitidieri E;Pharmacol. Ther.,2020

3. Psychosexual health and sexuality: multidisciplinary considerations in clinical practice;Tandon A;J. Psychosexual Health.,2023

4. Psychological distress in erectile dysfunction: the moderating role of attachment;Maestre-Lorén F;Sex. Med.,2021

5. An evaluation of psychogenic predictors of non-organic erectile dysfunction;Topak OZ;Medicina. (Kaunas).,2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3